The estimated Net Worth of Gregory Grunberg is at least $15.8 Миллион dollars as of 10 July 2020. Gregory Grunberg owns over 109,090 units of Kala Bio stock worth over $15,657,280 and over the last 7 years he sold KALA stock worth over $23,460. In addition, he makes $122,472 as Independent Director at Kala Bio.
Sign up
Gregory Grunberg KALA stock SEC Form 4 insiders trading
Gregory has made over 6 trades of the Kala Bio stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 850 units of KALA stock worth $23,460 on 21 April 2021.
The largest trade he's ever made was buying 2,534,854 units of Kala Bio stock on 13 March 2020 worth over $19,999,998. On average, Gregory trades about 237,697 units every 80 days since 2017. As of 10 July 2020 he still owns at least 2,600,877 units of Kala Bio stock.
You can see the complete history of Gregory Grunberg stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gregory Grunberg biography
Dr. Gregory Grunberg M.D. serves as Independent Director of the Company. Dr. Grunberg has been a Managing Director at Longitude Capital Management Co., LLC, a venture capital firm and a current 5% stockholder, or Longitude, since 2012 and has focused on drug development and medical technology solutions. Prior to joining Longitude, Dr. Grunberg was a Principal at Rho Ventures, a venture capital firm from 2007 to 2012, and an Engagement Manager at McKinsey & Company, a management consulting firm from 2004 to 2007. Dr. Grunberg is a board-certified physician in Internal Medicine and completed his residency at Cornell’s New York Presbyterian Hospital. He has maintained a limited clinical practice in Internal Medicine and affiliations with University of California, San Francisco and Kaiser Permanente. Dr. Grunberg currently serves on the boards of 89bio, Inc. and WelbeHealth LLC. He is also a board observer at Sydnexis, Inc. He previously served on the board of California Cryobank (acquired by GI Partners). While at Rho Ventures he served on the board of AqueSys (acquired by Allergan) and was a board observer at both SARCode Bioscience (acquired by Shire) and PHT (acquired by ERT). Dr. Grunberg holds an M.D. and an M.B.A from Duke University where he was a Fuqua Scholar and an A.B. in Economics and English from Amherst College. Grunberg’s experience with biotechnology companies qualifies him to serve as a member of our board of directors.
What is the salary of Gregory Grunberg?
As the Independent Director of Kala Bio, the total compensation of Gregory Grunberg at Kala Bio is $122,472. There are 13 executives at Kala Bio getting paid more, with Mark Iwicki having the highest compensation of $2,556,170.
How old is Gregory Grunberg?
Gregory Grunberg is 47, he's been the Independent Director of Kala Bio since 2016. There are 13 older and 4 younger executives at Kala Bio. The oldest executive at Kala Bio Inc. is Dr. Kim Brazzell Ph.D., 68, who is the Head of R&D and Chief Medical Officer.
What's Gregory Grunberg's mailing address?
Gregory's mailing address filed with the SEC is C/O 89BIO, INC., 142 SANSOME STREET, 2ND FLOOR, SAN FRANCISCO, CA, 94104.
Insiders trading at Kala Bio
Over the last 7 years, insiders at Kala Bio have traded over $2,579,128 worth of Kala Bio stock and bought 23,705,318 units worth $209,975,371 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Ra ... и Rajeev M. Shah. On average, Kala Bio executives and independent directors trade stock every 31 days with the average trade being worth of $2,090,132. The most recent stock trade was executed by Todd Bazemore on 26 June 2024, trading 4,653 units of KALA stock currently worth $22,102.
What does Kala Bio do?
kala pharmaceuticals, inc. (kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based mucus penetrating particles, or mpp, technology, with an initial focus on the treatment of eye diseases. for more information, please visit kala’s website at www.kalarx.com.
What does Kala Bio's logo look like?
Complete history of Gregory Grunberg stock trades at Kala Bio и 89bio Inc
Kala Bio executives and stock owners
Kala Bio executives and other stock owners filed with the SEC include:
-
Mark Iwicki,
Chairman of the Board, President, Chief Executive Officer -
Todd Bazemore,
Chief Operating Officer -
Eric Trachtenberg,
Chief Compliance Officer, General Counsel, Secretary -
Kim Brazzell,
Chief Medical Officer -
Mark T. Iwicki,
Chairman & CEO -
Dr. Kim Brazzell Ph.D.,
Head of R&D and Chief Medical Officer -
Hongming Chen,
Chief Scientific Officer -
Todd Bazemore,
Pres & COO -
Andrew Koven,
Lead Independent Director -
Rajeev Shah,
Independent Director -
Gregory Perry,
Independent Director -
Robert Paull,
Independent Director -
Howard Rosen,
Independent Director -
Gregory Grunberg,
Independent Director -
Hannah Deresiewicz,
IR Contact Officer -
Mary Reumuth,
Chief Financial Officer, Treasurer -
James Patnoe,
Sr. VP of Market Access, Commercial Operations & Pricing -
Vincent Kosewski,
Sr. VP of Manufacturing & Supply Chain Management -
Michele LaRussa,
Sr. VP of Regulatory Affairs & Quality Assurance -
Kathleen McCann Kline,
Sr. VP of Marketing -
Eric L. Trachtenberg,
Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
Jill S. Steier,
Exec. Director of Investor Relations & Corp. Communications -
Mary Reumuth CPA, CPA,
CFO & Treasurer -
Dr. Justin Hanes Ph.D.,
Founder & Chair of the Scientific Advisory Board -
Capital Partners Ii, Llcenr...,
-
Harbor Master Investors (Ca...,
10% owner -
Associates, L.L.C.Caxton Co...,
-
Paulina Hill,
Director -
Advisors Llc Orbi Med Capit...,
-
Capital Management, L.P.Ra ...,
-
Robert I Tepper,
Director -
Robert Langer,
Director -
Advisors Llc Orbi Med Capit...,
-
Michele La Russa,
Sr. VP, Regulatory and Quality -
C. Daniel Myers,
-
Marjan Farid,
-
Capital Management, L.P.Ra ...,
-
Romulus K Brazzell,
SEE REMARKS -
Mark S. Blumenkranz,
-
Darius Kharabi,
CHIEF BUSINESS OFFICER